Publications by authors named "C-K How"
Real-world efficacy of low dose osimertinib as second-line treatment in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer.
Mau Ern Poh Sivasubramaniam Balakrishnan Sin Nee Tan Muhammad Adil Zainal Abidin Chong Kin Liam Soon Hin How
Transl Lung Cancer Res
July 2024
Article Synopsis
- This study examined the effectiveness and safety of lower doses of osimertinib (20 mg and 40 mg daily) for patients with advanced NSCLC who had previously failed other treatments, compared to the standard 80 mg daily dose.
- Researchers analyzed data from 22 patients who had the EGFR T790M mutation and found that lower doses resulted in a notable overall response rate of 77.3%, with median progression-free survival of 10 months and overall survival of 13 months.
- The findings suggest that even patients with poor performance status (ECOG 3 or 4) experienced decent survival outcomes, emphasizing that lower doses of osimertinib could be a viable treatment
Induced pluripotent stem cells alleviate lung injury from mesenteric ischemia-reperfusion.
J Trauma Acute Care Surg
October 2015
Background: Mesenteric ischemia-reperfusion (I/R) injury is a serious pathophysiologic process that can trigger the development of multiorgan dysfunction. Acute lung injury is a major cause of death among mesenteric I/R patients, as current treatments remain inadequate. Stem cell-based therapies are considered novel strategies for treating several devastating and incurable diseases.
View Article and Find Full Text PDF